Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial
Koch Raphael , Haveman Lianne , Ladenstein Ruth , BRICHARD Bénédicte , Juergens Heribert , Cyprová Soňa , Berg den van Henk , Hassenpflug Wolf , Raciborska Anna , Ek Torben , Baumhoer Daniel , Egerer Gerlinde , Kager Leo , Renard Marleen , Hauser Peter , Burdach Stefan , Bovee V.M.G. Judith , Hong M. Angela , Reichardt Peter , Kruseova Jarmila , Streitbürger Arne , Kühne Thomas , Kessler Torsten , Bernkopf Marie , Butterfaß-Bahloul Trude , Dhooge Catharina , Bauer Sebastian , Kiss János , Paulussen Michael , Bonar Fiona , Ranft Andreas , Timmermann Beate , Rascon Jelena , Vieth Volker , Kanerva Jukka , Faldum Andreas , Hartmann Wolfgang , Hjorth Lars , Bhadri A. Vivek , Metzler Markus , Gelderblom Hans , Dirksen Uta
Research article (journal) | Peer reviewedDetails about the publication
Journal: Clinical Cancer Research (Clin Cancer Res)
Volume: ahead of print
Status: Published
Release year: 2023 (10/04/2024)
Language in which the publication is written: English
Link to the full text: https://doi.org/10.1158/1078-0432.CCR-23-1966
Keywords: Ewing Sarcoma; zoledronic acid; Ewing2008; localized Ewing Sarcoma; maintenance therapy
Authors from the University of Münster
| Faldum, Andreas | Institute of Biostatistics and Clinical Research (IBKF) |
| Keßler, Torsten | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
| Koch, Raphael | Institute of Biostatistics and Clinical Research (IBKF) |